Yükleniyor... / Loading...
This study examines the effect of therapeutic bloodletting (phlebotomy) on iron metabolism in people with Type 1 Hemochromatosis (an inherited disease causing iron accumulation). It included men over 18 homozygous for the C282Y mutation in the HFE gene, with high ferritin and transferrin saturation, who had never had phlebotomy. It is a non-phase study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Men * Age 18 years or older * Homozygosity for the C282Y mutation of the HFE gene * With an indication of treatment by bloodletting (in accordance with the French HAS guidelines) * Ferritinemia ≥ 500µg/L * Transferrin saturation ≥ 75% * Never treated by bloodletting * Written informed consent Exclusion Criteria: * Contraindication to bloodletting * Chronic inflammatory or dysmetabolic or neoplastic disease * Major cardiovascular disease * Excessive consumption of alcohol (≥ 3gr/day) * Treatment by iron chelators, C or E vitamins * Stay in altitude\> 1500m in the month preceding the period Day 1 * Patients under guardianship * Blood donation in the 3 past months * Night / shift workers